Indications and usage of Cerebrolysin:
Alzheimer disease, dementia syndrome of various origin, cerebrovascular insufficiency, ischaemic stroke, traumatic brain injuries, mental retardation in children, attention deficit disorder in children, hyperactivity in children, as part of complex treatment – endogenous depression resistant to antidepressants.
Contraindications: hypersensitivity to drug components; severe renal insufficiency; epileptic status.
Dosage and administration:
For parenteral administration. Doses and treatment duration depends on the disease nature and severity, as well as on the patient’s age.
The recommended effective treatment regimen contains regular daily injections for 10-20 days.
Acute conditions (ischaemic stroke, craniocerebral injury, post-neurosurgical complications) – from 10 to 50 ml;
During residual period of cerebral stroke and traumatic brain injury – from 5 to 50 ml;
Psychoorganic syndrome and depression – from 5 to 30 ml;
Alzheimer disease, mental disability of vascular and concomitant Alzheimer-vascular origin – from 5 to 30 ml;
Neuropaediatrics – 0,1-0,2 ml/kg of body weight.
To improve therapy efficacy retreatment courses may be given.
Cerebrolysin is administered in from of injections: intramuscular introduction (up to 5 ml) and intravenous introduction (up to 10 ml). Doses from 10 ml to 50 ml are administered in form of slow intravenous infusions (Cerebrolysin is diluted with solution for infusions). Infusion duration is 15-60 minutes.
Overdosage: there is no information available.
Precautions: Cerebrolysin may be used simultaneously with vitamins and medications improving heart circulation, but these medications should not be mixed in one syringe with Cerebrolysin.